Citation Tools
PDFRegular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90%
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90%